Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACT201 in Healthy Participants and Participants With Chronic Hepatitis B
NCT07741461Phase 1Recruiting
- Sponsor
- Xiamen Tebao Biological Engineering Co., Ltd.
- Start
- Aug 2026
- Primary completion
- Mar 2027
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in Chronic Hepatitis B (CHB) comparing ACT201 Injection group with ACT201 Injection Placebo (2 arms). Primary endpoint: Number of participants with adverse event (AE), serious adverse events (SAE) and clinically significant examination results at 4 months. Started Aug 2026; status: recruiting.
02
Drugs
ACT201
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT07741461.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07741461.